Ulocuplumab is a monoclonal antibody that specifically targets the human chemokine receptor CCR4, which plays a significant role in the immune system and is implicated in various diseases, including certain types of cancer and autoimmune disorders. As a therapeutic agent, Ulocuplumab is designed to modulate immune responses by blocking the interaction between CCR4 and its ligands, thereby inhibiting the migration of CCR4-expressing cells, such as regulatory T cells, to sites of inflammation or tumor growth. This mechanism of action makes it a candidate for treating conditions like peripheral T-cell lymphoma and other malignancies. Ulocuplumab is typically administered via injection and has undergone various clinical trials to assess its efficacy and safety profile. Its development reflects a growing trend in biopharmaceuticals focusing on targeted therapies that leverage the body's immune system to combat disease. As with many monoclonal antibodies, potential side effects may include infusion reactions and increased susceptibility to infections, necessitating careful monitoring during treatment.

Ulocuplumab

1375830-34-4: Ulocuplumab is a monoclonal antibody that specifically targets the human chemokine receptor CCR4, which plays a significant role in the immune system and is implicated in various diseases, including certain types of cancer and autoimmune disorders. As a therapeutic agent, Ulocuplumab is designed to modulate immune responses by blocking the interaction between CCR4 and its ligands, thereby inhibiting the migration of CCR4-expressing cells, such as regulatory T cells, to sites of inflammation or tumor growth. This mechanism of action makes it a candidate for treating conditions like peripheral T-cell lymphoma and other malignancies. Ulocuplumab is typically administered via injection and has undergone various clinical trials to assess its efficacy and safety profile. Its development reflects a growing trend in biopharmaceuticals focusing on targeted therapies that leverage the body's immune system to combat disease. As with many monoclonal antibodies, potential side effects may include infusion reactions and increased susceptibility to infections, necessitating careful monitoring during treatment.

Ulocuplumab is a human anti-CXCR4 IgG4 antibody tackling AML, NHL, and multiple myeloma; induces CLL apoptosis.

<p>Monoclonal antibody targeting C-X-C chemokine receptor type 4; treatment of hematologic malignancies</p>

CAS 1375830-34-4

Ulocuplumab

Ulocuplumab

Ref: TM-T76794

Ulocuplumab

Ref: 3D-CLA1347